Stemora, Inc
Stemora Inc. is a regenerative-medicine company (founded 2025, Frederick, Maryland) developing a one-step, intraoperative therapy that aims to restore native hyaline cartilage by activating the patient’s own skeletal stem cells. The company integrates stem cell biology, biomaterials engineering, and orthopedic translational research and is in preclinical development, supported by competitive grant funding.
Industries
Nr. of Employees
small (1-50)
Products
One-step intraoperative regenerative therapy for cartilage repair
An investigational, single‑procedure intraoperative therapy that activates and guides local stem cells and uses a controlled‑release biomaterial system to regenerate durable hyaline cartilage in focal defects.
One-step intraoperative regenerative therapy for cartilage repair
An investigational, single‑procedure intraoperative therapy that activates and guides local stem cells and uses a controlled‑release biomaterial system to regenerate durable hyaline cartilage in focal defects.
Services
In-house preclinical R&D and translational study execution to advance regenerative cartilage therapies toward clinical evaluation.
In-house preclinical R&D and translational study execution to advance regenerative cartilage therapies toward clinical evaluation.
Expertise Areas
- Regenerative medicine
- Cartilage regeneration and repair
- Biomaterials engineering
- Translational preclinical research
Key Technologies
- Endogenous skeletal stem cell activation
- Controlled‑release biomaterials
- Intraoperative minimally invasive delivery
- Hyaline cartilage regeneration approaches
News & Updates
Announcement of a $305,000 NSF SBIR Phase I award to support development of a one‑step intraoperative regenerative therapy and advancement of a controlled‑release biomaterial delivery system in translational preclinical models.
Awarded a $305,000 National Science Foundation Small Business Innovation Research Phase I grant to support preclinical development of a one‑step intraoperative regenerative cartilage therapy.
Announcement of a $305,000 NSF SBIR Phase I award to support development of a one‑step intraoperative regenerative therapy and advancement of a controlled‑release biomaterial delivery system in translational preclinical models.
Awarded a $305,000 National Science Foundation Small Business Innovation Research Phase I grant to support preclinical development of a one‑step intraoperative regenerative cartilage therapy.